Last Update: May 27, 2026 PSMAcTION: A Phase II/III, Open-label, International, Multicenter, Randomized Study of AAA817 Versus Standard of Care in the Treatment of Adult Participants With PSMA Positive Metastatic Castration-resistant Prostate Cancer Who Progressed on or After [177Lu]Lu-PSMA Targeted Therapy ClinicalTrials.gov Identifier: [NCT06780670](https://clinicaltrials.gov/ct2/show/NCT06780670) Novartis Reference Number:CAAA817A12201 [See if you Pre-qualify](#trial-eligibility "See if you Pre-qualify") All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. ## Study Description This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after \\\[177Lu\\\]Lu-PSMA targeted therapy. Treatment of interest: the investigational treatment is AAA817 regardless of subsequent anti-neoplastic treatment. The control treatment is investigator's choice of Standard of Care, regardless of subsequent anti-neoplastic treatment Study CAAA817A12201 consists of 2 parts: a randomized, open-label, international, multicenter, phase II study (Phase II) to collect more information to support the proposed dose of AAA817 and a randomized, open-label, international, multicenter, 2- arm phase III study (Phase III) aimed to evaluate the efficacy and safety of proposed dose of AAA817 vs. investigator's choice of standard of care (SoC) in the treatment of adult participants with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who had treatments with ARPI and taxane-based chemotherapy, and progressed on or after \\\[177Lu\\\]Lu-PSMA targeted therapy. The purpose of the phase II part (Phase II) of this study is to collect additional information to support proposed phase III dose of AAA817. Condition Prostate Cancer Phase Phase2, Phase3 Overall Status Recruiting Number of Participants443 Start Date Feb 27, 2025 Completion Date Jul 19, 2033 Gender Male Age(s) 18 Years - 100 Years (Adult, Older Adult) ## Interventions Drug ### AAA817 Investigational treatment is the Dose B of AAA817 Drug ### Investigators choice of SoC The control treatment in Phase III is investigator's choice of SoC ## Eligibility Criteria Inclusion Criteria: ∙ \* adults ≥ 18 years of age. \* ECOG performance status of 0 to 2. \* histopathological and/or cytological confirmation of adenocarcinoma of the prostate. \* PSMA-positive disease as assessed by PSMA PET/CT scan using an approved PSMA imaging agent as protocol instructed, \* castrate level of serum/plasma testosterone (\\< 50 ng/dL or \\< 1.7 nmol/L). \* Prior treatments with an androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy, and progressed on or after \\\[177Lu\\\]Lu-PSMA targeted therapy. \* ≥ 1 metastatic lesion that is present on screening/baseline CT, MRI, or bone scan imaging obtained ≤ 28 days prior to randomization \* eGFR as requested by the sponsor Exclusion Criteria: \* Any investigational agents within 28 days prior to the day of randomization. \* Any 225Ac-based investigational compound used prior to the day of randomization. \* Participants with a history of CNS metastases who are neurologically unstable, symptomatic, or receiving corticosteroids for the purpose of maintaining neurologic integrity. \* Concurrent acute kidney injury (renal failure developed between 48 hours to 7 days) or chronic kidney disease (at least 3 months of ongoing renal injury) \* Baseline xerostomia ≥ Grade 2 by CTCAE v.5 \* History of uncontrolled hypertension, myocardial infarction (MI), angina pectoris, or coronary artery bypass graft (CABG) within 6 months prior to ICF signature and/or clinically active significant cardiac disease \* History of lymphoproliferative disease or any known malignancy or history of malignancy of any organ system within the past 5 years (except for basal cell carcinoma or actinic keratosis that have been treated with no evidence of recurrence in the past 3 months, non-invasive malignant colon polyps that have been removed). Other protocol-defined inclusion/exclusion criteria may apply. Australia #### Novartis Investigative Site Recruiting Darlinghurst,New South Wales,2010,Australia #### Novartis Investigative Site Recruiting Herston,Queensland,4029,Australia #### Novartis Investigative Site Recruiting Melbourne,Victoria,3004,Australia Brazil #### Novartis Investigative Site Recruiting São Paulo,São Paulo,05652-000,Brazil #### Novartis Investigative Site Recruiting São Paulo,São Paulo,01308-050,Brazil China #### Novartis Investigative Site Recruiting Beijing,100036,China #### Novartis Investigative Site Recruiting Chengdu,Sichuan,610041,China #### Novartis Investigative Site Recruiting Nanjing,Jiangsu,210029,China #### Novartis Investigative Site Recruiting Shanghai,200032,China #### Novartis Investigative Site Recruiting Wuhan,Hubei,430022,China #### Novartis Investigative Site Recruiting Nanjing,Jiangsu,210006,China #### Novartis Investigative Site Recruiting Wuhan,Hubei,430030,China #### Novartis Investigative Site Recruiting Shenyang,Liaoning,110011,China #### Novartis Investigative Site Recruiting Xian,Shanxi,710032,China #### Novartis Investigative Site Recruiting Xian,Shanxi,710061,China #### Novartis Investigative Site Recruiting Beijing,100034,China #### Novartis Investigative Site Recruiting Guangzhou,510060,China #### Novartis Investigative Site Recruiting Shanghai,200025,China #### Novartis Investigative Site Recruiting Fuzhou,Fujian,350025,China #### Novartis Investigative Site Recruiting Tianjin,300300,China Hong Kong #### Novartis Investigative Site Recruiting Hong Kong,999077,Hong Kong Israel #### Novartis Investigative Site Recruiting Tel Aviv,6423906,Israel #### Novartis Investigative Site Recruiting Petah Tikva,4941492,Israel #### Novartis Investigative Site Recruiting Ramat Gan,5265601,Israel #### Novartis Investigative Site Recruiting Haifa,3109601,Israel #### Novartis Investigative Site Recruiting Beersheba,8457108,Israel #### Novartis Investigative Site Recruiting Jerusalem,9112001,Israel Japan #### Novartis Investigative Site Recruiting Chiba,260-8717,Japan #### Novartis Investigative Site Recruiting Kobe,Hyōgo,6500047,Japan #### Novartis Investigative Site Recruiting Fukuoka,8128582,Japan #### Novartis Investigative Site Recruiting Kyoto,6068507,Japan #### Novartis Investigative Site Recruiting Fukuoka,812-0033,Japan #### Novartis Investigative Site Recruiting Ishikawa,9208641,Japan #### Novartis Investigative Site Recruiting Fukushima,9601295,Japan #### Novartis Investigative Site Recruiting Kashiwa,Chiba,277-8577,Japan #### Novartis Investigative Site Recruiting Sapporo,Hokkaido,060-8648,Japan #### Novartis Investigative Site Recruiting Yokohama,Kanagawa,236-0004,Japan #### Novartis Investigative Site Recruiting Fukuoka,811-0213,Japan Malaysia #### Novartis Investigative Site Recruiting Petaling Jaya,Selangor,46050,Malaysia #### Novartis Investigative Site Recruiting Petaling Jaya,Selangor,46150,Malaysia Singapore #### Novartis Investigative Site Recruiting Singapore,168583,Singapore #### Novartis Investigative Site Recruiting Singapore,119228,Singapore #### Novartis Investigative Site Recruiting Singapore,258499,Singapore South Korea #### Novartis Investigative Site Recruiting Seoul,05505,South Korea #### Novartis Investigative Site Recruiting Seoul,03080,South Korea #### Novartis Investigative Site Recruiting Seoul,03722,South Korea #### Novartis Investigative Site Recruiting Seoul,06591,South Korea Switzerland #### Novartis Investigative Site Recruiting Bern,3010,Switzerland #### Novartis Investigative Site Recruiting Basel,4031,Switzerland #### Novartis Investigative Site Recruiting Bellinzona,6500,Switzerland Taiwan #### Novartis Investigative Site Recruiting Taipei,10002,Taiwan #### Novartis Investigative Site Recruiting Taipei,103616,Taiwan #### Novartis Investigative Site Recruiting Taipei,11217,Taiwan #### Novartis Investigative Site Recruiting Taoyuan,33305,Taiwan United States #### Dana Farber Cancer Institute Recruiting Boston,Massachusetts,02115,United States ###### Michael Bonhomme Phone: [617-632-5136](tel:617-632-5136) Email: [michael\_bonhomme@dfci.harvard.edu](mailto:michael_bonhomme@dfci.harvard.edu) ###### Xiao Wei. #### WA Uni School Of Med Recruiting St Louis,Missouri,63110,United States ###### Collin Welch Phone: [314-454-8293](tel:314-454-8293) Email: ###### Jeff Michalski #### Indiana University Recruiting Indianapolis,Indiana,46202,United States ###### Marie Burton Email: ###### Nabil Adra #### VA Greater LA Healthcare System Recruiting Los Angeles,California,90073,United States ###### Gholam Reza Berenji ###### Janake Wijesuriya Email: #### University Cancer and Blood Center LLC Recruiting Athens,Georgia,30607,United States ###### Christen Nicole Cooper Pope Phone: [+1 706 353 2990]() Email: ###### Petros Nikolinakos #### University of Kansas Hospital Recruiting Kansas City,Kansas,66160,United States ###### Kelsey Schwensen Email: ###### Xinglei Shen #### Nebraska Cancer Specialists Recruiting Omaha,Nebraska,68154,United States ###### Marlene Bridwell Phone: [402-334-4773](tel:402-334-4773) Email: ###### Samuel Mehr #### Medical College Of Wisconsin Recruiting Milwaukee,Wisconsin,53226,United States ###### Deepak Kilari ###### Nadia Thomas Email: #### Associated Med Professionals of NY Recruiting Syracuse,New York,13210,United States ###### Nathan Forrest Email: ###### Steven Finkelstein #### Stanford University Medical Center Recruiting Palo Alto,California,94304,United States ###### Hong Song ###### Mikayla Easterling Email: #### New Jersey Urology LLC Recruiting Voorhees Township,New Jersey,08043,United States ###### Gabriela Mercado Phone: [856-673-1613](tel:856-673-1613) Email: ###### Gordon Brown #### Montefiore Medical Center Recruiting The Bronx,New York,10467,United States ###### Benjamin A Gartrell ###### Tahrima Chowdhury Phone: [718-920-6642](tel:718-920-6642) Email: #### Carolina Urologic Research Center Recruiting Myrtle Beach,South Carolina,29572,United States ###### Neal D Shore ###### Rebecca Floyd Phone: [843-839-1679](tel:843-839-1679) Email: #### Urology San Antonio Recruiting San Antonio,Texas,78229,United States ###### Daniel Saltzstein ###### Sandra Davila Email: #### Sansum Clinic Recruiting Santa Barbara,California,93105,United States ###### Gregg Newman ###### Jessica Wong Phone: [805-563-5800](tel:805-563-5800) Email: #### Saint Johns Cancer Institute Recruiting Santa Monica,California,90404,United States ###### Joey Dumadag Phone: [310-829-8569](tel:310-829-8569) Email: ###### Przemyslaw Twardowski #### Hartford Hospital Recruiting Hartford,Connecticut,06102,United States ###### Andrew Salner ###### Melanie Manning Email: #### AdventHealth Recruiting Orlando,Florida,32804,United States ###### Joseph Guzzo Phone: [407-303-3235](tel:407-303-3235) Email: ###### Ravi Shridhar #### Emory University Recruiting Atlanta,Georgia,30322,United States ###### Jalpa Patel Phone: [+1 404 778 1835]() Email: ###### Shahid Sattar Ahmed. #### Central Ohio Urology Group Recruiting Gahanna,Ohio,43230,United States ###### Benjamin Martin ###### Sarah Faisal Email: #### Texas Oncology Recruiting Dallas,Texas,75251,United States ###### Marian Heaven Phone: [512-427-9467](tel:512-427-9467) Email: ###### Michael P Herman #### Utah Intermountain Medical Center Recruiting Murray,Utah,84107,United States ###### Becky Arroyo Email: ###### David Gill #### East Jefferson Hospital Recruiting Metairie,Louisiana,70006,United States ###### Alexandra Lieberman Email: ###### Alton Oliver Sartor #### Beth Israel Deaconess Medical Center Recruiting Boston,Massachusetts,02215,United States ###### David J Einstein ###### Ooviya Sathiyamoorthy Phone: [617-643-9923](tel:617-643-9923) Email: #### Fox Chase Cancer Center Recruiting Philadelphia,Pennsylvania,19111,United States ###### Candice Schewbel Phone: [215-728-3075](tel:215-728-3075) Email: ###### Matthew Zibelman #### Fred Hutchinson Cancer Research Center Recruiting Seattle,Washington,98109-1024,United States ###### Brianna Woo Email: ###### Ruben Raychaudhuri #### VA Palo Alto Health Care System Recruiting Palo Alto,California,94304-1207,United States ###### Minal Vasanawala ###### Niko Del Mar Phone: [650-493-5000](tel:650-493-5000) Email: ## Worldwide Contacts If the location of your choosing does not feature any contact detail, please reach out using the information below. #### Novartis Pharmaceuticals Phone: [ +41613241111](tel:+41613241111) Email: [](mailto:) #### Novartis Pharmaceuticals Phone: [ 1-888-669-6682](tel:1-888-669-6682) Email: